Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
about
Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMAThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Cancer and schizophrenia: is there a paradox?The evolution of hyperprolactinaemia as an entity in psychiatric patients.Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).A review of the association between antipsychotic use and hyperprolactinaemia.A well-being programme in severe mental illness. Baseline findings in a UK cohort.The Effects of Antipsychotics on Prolactin Levels and Women's Menstruation.Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.Antipsychotic-induced hyperprolactinaemia.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis."First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects.Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.Lack of tolerable treatment options for patients with schizophrenia.Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.Prolactin and smoking status in antipsychotic-treated patients.The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness.
P2860
Q26775158-86E093AA-99A5-4B00-B467-C74C273C698BQ33619940-374EBC0D-87F4-4A9B-84DA-99EB10ACD4E8Q34026011-BB21A5A7-15FD-429C-A0B5-A9B0418127AFQ34037969-43F0D9BB-D051-44CA-B5BC-B2C049127F8CQ34183508-130E39A4-A0E0-4F29-88F1-795B2E4D0123Q34591930-508815CC-22AA-4D7E-A5CE-8C2AE7B2EAFEQ34966395-FDFA8845-A4A3-4680-94D0-3052F3B0A183Q37162798-103CC1A7-30D9-428B-9BD9-A313B9A540B9Q37427322-460FF48D-78C6-4218-B141-F487EF3C6B17Q37456024-388A7746-9ABB-4E81-88A5-26C76D363C0FQ37747570-17013417-0198-4738-A3F6-EB45CDE93BA1Q37895702-FB688393-43B1-49D4-8794-2DC3A9E2E6CEQ37999566-B75091DC-9B6E-4C6B-963C-9154DED2915DQ38291338-D6E4E6B1-3A0A-4EF5-B29D-CDD99F8A8FC6Q38858121-3E87C2A7-C062-479D-80BA-A723AFE3CA8AQ42120078-26FE1FAE-E009-4585-AD99-A23D4BAFEAC0Q46110645-C1B5EE78-7035-45F1-B403-7DC16B8FF0E3Q46597827-28752F7B-A934-452B-9581-58B03FF33ACFQ48397820-4AF05688-7BD4-43AD-8FAF-9C46769BCC0BQ51843055-0FCC4107-CFBC-4815-80B4-5B25F58EF375Q51887432-BBC7FB0D-4ACF-49B4-BF86-5144C39E1EFD
P2860
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@en
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@nl
type
label
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@en
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@nl
prefLabel
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@en
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@nl
P2860
P356
P1476
Prevalence of hyperprolactinae ...... l and atypical antipsychotics.
@en
P2093
Chris Bushe
Michael Shaw
P2860
P304
P356
10.1177/0269881107078281
P407
P577
2007-07-02T00:00:00Z